Evidence map›Paper›PMID 42279438›Full record

ReviewCancers2026

Computer Vision for Predicting the Efficacy of Neoadjuvant Therapy in Breast Cancer.

Daria Sitnikova, Alexey Fayzullin, Fedor Chistov, Peter Timashev, Nikita Savelov

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daria SitnikovaInstitute for Regenerative Medicine, Sechenov University, 8-2 Trubetskaya St., 119991 Moscow, Russia.
Alexey FayzullinInstitute for Regenerative Medicine, Sechenov University, 8-2 Trubetskaya St., 119991 Moscow, Russia.ORCID 0000-0003-4137-8993
Fedor ChistovMoscow City Oncology Hospital No. 62, 27 Istra, 143515 Moscow, Russia.
Peter TimashevInstitute for Regenerative Medicine, Sechenov University, 8-2 Trubetskaya St., 119991 Moscow, Russia.
Nikita SavelovMoscow City Oncology Hospital No. 62, 27 Istra, 143515 Moscow, Russia.

Funding

Russian Science Foundation 25-25-01045
6 · The paper itself

Abstract

Neoadjuvant therapy (NAT) is a standard component of breast cancer treatment, yet response rates vary substantially across patients. Accurate prediction of pathological complete response remains an unmet clinical need to improve patient selection for NAT. This review summarizes current approaches of using computer vision to predict breast cancer response to NAT from histopathological slides. We examined studies employing computer vision and machine learning models on hematoxylin and eosin and immunohistochemically stained whole-slide images, focusing on morphological features of tumor cells, stroma and tumor-infiltrating lymphocytes associated with pathological complete response. Key morphological predictors of therapy resistance included low tumor cell density with cord-like patterns, necrosis, predominance of collagenous and fibroblast-rich stroma and tumor vascularization, while therapy sensitivity was associated with high nuclear staining intensity, high tumor cell density and lymphocyte infiltration. We highlighted the advantages of incorporating multimodal data to enhance predictive performance. Our analysis demonstrates that computer vision models can detect subtle morphological patterns that may be difficult for pathologists to evaluate, providing valuable insights for personalized therapy planning in breast cancer. Further development of cross-modal, interpretable artificial intelligence solutions may improve prediction accuracy and deepen our understanding of tumor biology relevant to NAT response.

Indexed as

breast cancercomputer visiondigital pathologyneoadjuvantpathological response

Identifiers

PMID42279438
PMCPMC13256785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.